188 related articles for article (PubMed ID: 35697379)
21. ZEB1 transcription factor promotes immune escape in melanoma.
Plaschka M; Benboubker V; Grimont M; Berthet J; Tonon L; Lopez J; Le-Bouar M; Balme B; Tondeur G; de la Fouchardière A; Larue L; Puisieux A; Grinberg-Bleyer Y; Bendriss-Vermare N; Dubois B; Caux C; Dalle S; Caramel J
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35288462
[TBL] [Abstract][Full Text] [Related]
22. Targeting the cytosolic innate immune receptors RIG-I and MDA5 effectively counteracts cancer cell heterogeneity in glioblastoma.
Glas M; Coch C; Trageser D; Dassler J; Simon M; Koch P; Mertens J; Quandel T; Gorris R; Reinartz R; Wieland A; Von Lehe M; Pusch A; Roy K; Schlee M; Neumann H; Fimmers R; Herrlinger U; Brüstle O; Hartmann G; Besch R; Scheffler B
Stem Cells; 2013 Jun; 31(6):1064-74. PubMed ID: 23390110
[TBL] [Abstract][Full Text] [Related]
23. Nanoparticle Retinoic Acid-Inducible Gene I Agonist for Cancer Immunotherapy.
Wang-Bishop L; Wehbe M; Pastora LE; Yang J; Kimmel BR; Garland KM; Becker KW; Carson CS; Roth EW; Gibson-Corley KN; Ulkoski D; Krishnamurthy V; Fedorova O; Richmond A; Pyle AM; Wilson JT
ACS Nano; 2024 May; 18(18):11631-11643. PubMed ID: 38652829
[TBL] [Abstract][Full Text] [Related]
24. Interleukin 32 expression in human melanoma.
Paz H; Tsoi J; Kalbasi A; Grasso CS; McBride WH; Schaue D; Butterfield LH; Maurer DM; Ribas A; Graeber TG; Economou JS
J Transl Med; 2019 Apr; 17(1):113. PubMed ID: 30953519
[TBL] [Abstract][Full Text] [Related]
25. Targeting nucleic acid sensors in tumor cells to reprogram biogenesis and RNA cargo of extracellular vesicles for T cell-mediated cancer immunotherapy.
Heidegger S; Stritzke F; Dahl S; Daßler-Plenker J; Joachim L; Buschmann D; Fan K; Sauer CM; Ludwig N; Winter C; Enssle S; Li S; Perl M; Görgens A; Haas T; Orberg ET; Göttert S; Wölfel C; Engleitner T; Cortés-Ciriano I; Rad R; Herr W; Giebel B; Ruland J; Bassermann F; Coch C; Hartmann G; Poeck H
Cell Rep Med; 2023 Sep; 4(9):101171. PubMed ID: 37657445
[TBL] [Abstract][Full Text] [Related]
26. Acquired cancer stem cell phenotypes through Oct4-mediated dedifferentiation.
Kumar SM; Liu S; Lu H; Zhang H; Zhang PJ; Gimotty PA; Guerra M; Guo W; Xu X
Oncogene; 2012 Nov; 31(47):4898-911. PubMed ID: 22286766
[TBL] [Abstract][Full Text] [Related]
27. Co-stimulation through 4-1BB/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy.
Chacon JA; Wu RC; Sukhumalchandra P; Molldrem JJ; Sarnaik A; Pilon-Thomas S; Weber J; Hwu P; Radvanyi L
PLoS One; 2013; 8(4):e60031. PubMed ID: 23560068
[TBL] [Abstract][Full Text] [Related]
28. PD-1
Donia M; Kjeldsen JW; Andersen R; Westergaard MCW; Bianchi V; Legut M; Attaf M; Szomolay B; Ott S; Dolton G; Lyngaa R; Hadrup SR; Sewell AK; Svane IM
Clin Cancer Res; 2017 Oct; 23(19):5779-5788. PubMed ID: 28679768
[No Abstract] [Full Text] [Related]
29. Tissue-resident memory T cells from a metastatic vaginal melanoma patient are tumor-responsive T cells and increase after anti-PD-1 treatment.
Pizzolla A; Keam SP; Vergara IA; Caramia F; Thio N; Wang M; Kocovski N; Tantalo D; Jabbari J; Au-Yeung G; Sandhu S; Gyorki DE; Weppler A; Perdicchio M; McArthur GA; Papenfuss AT; Neeson PJ
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35550554
[TBL] [Abstract][Full Text] [Related]
30. RIG-I activation induces the release of extracellular vesicles with antitumor activity.
Daßler-Plenker J; Reiners KS; van den Boorn JG; Hansen HP; Putschli B; Barnert S; Schuberth-Wagner C; Schubert R; Tüting T; Hallek M; Schlee M; Hartmann G; Pogge von Strandmann E; Coch C
Oncoimmunology; 2016; 5(10):e1219827. PubMed ID: 27853642
[TBL] [Abstract][Full Text] [Related]
31. RIG-I inhibits the MAPK-dependent proliferation of BRAF mutant melanoma cells via MKP-1.
Szabo A; Fekete T; Koncz G; Kumar BV; Pazmandi K; Foldvari Z; Hegedus B; Garay T; Bacsi A; Rajnavolgyi E; Lanyi A
Cell Signal; 2016 May; 28(5):335-347. PubMed ID: 26829212
[TBL] [Abstract][Full Text] [Related]
32. Collagen abundance controls melanoma phenotypes through lineage-specific microenvironment sensing.
Miskolczi Z; Smith MP; Rowling EJ; Ferguson J; Barriuso J; Wellbrock C
Oncogene; 2018 Jun; 37(23):3166-3182. PubMed ID: 29545604
[TBL] [Abstract][Full Text] [Related]
33. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
[TBL] [Abstract][Full Text] [Related]
34. RIG-I activation is critical for responsiveness to checkpoint blockade.
Heidegger S; Wintges A; Stritzke F; Bek S; Steiger K; Koenig PA; Göttert S; Engleitner T; Öllinger R; Nedelko T; Fischer JC; Makarov V; Winter C; Rad R; van den Brink MRM; Ruland J; Bassermann F; Chan TA; Haas T; Poeck H
Sci Immunol; 2019 Sep; 4(39):. PubMed ID: 31519811
[TBL] [Abstract][Full Text] [Related]
35. B cells imprint adoptively transferred CD8
Smith AS; Knochelmann HM; Wyatt MM; Rangel Rivera GO; Rivera-Reyes AM; Dwyer CJ; Ware MB; Cole AC; Neskey DM; Rubinstein MP; Liu B; Thaxton JE; Bartee E; Paulos CM
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35017148
[TBL] [Abstract][Full Text] [Related]
36. Melanoma suppression by quercein is correlated with RIG-I and type I interferon signaling.
Peng D; Chen L; Sun Y; Sun L; Yin Q; Deng S; Niu L; Lou F; Wang Z; Xu Z; Wang C; Fan L; Wang H; Wang H
Biomed Pharmacother; 2020 May; 125():109984. PubMed ID: 32066042
[TBL] [Abstract][Full Text] [Related]
37. Intratumoral Tcf1
Siddiqui I; Schaeuble K; Chennupati V; Fuertes Marraco SA; Calderon-Copete S; Pais Ferreira D; Carmona SJ; Scarpellino L; Gfeller D; Pradervand S; Luther SA; Speiser DE; Held W
Immunity; 2019 Jan; 50(1):195-211.e10. PubMed ID: 30635237
[TBL] [Abstract][Full Text] [Related]
38. 5'-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma.
Poeck H; Besch R; Maihoefer C; Renn M; Tormo D; Morskaya SS; Kirschnek S; Gaffal E; Landsberg J; Hellmuth J; Schmidt A; Anz D; Bscheider M; Schwerd T; Berking C; Bourquin C; Kalinke U; Kremmer E; Kato H; Akira S; Meyers R; Häcker G; Neuenhahn M; Busch D; Ruland J; Rothenfusser S; Prinz M; Hornung V; Endres S; Tüting T; Hartmann G
Nat Med; 2008 Nov; 14(11):1256-63. PubMed ID: 18978796
[TBL] [Abstract][Full Text] [Related]
39. Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook.
Wu R; Forget MA; Chacon J; Bernatchez C; Haymaker C; Chen JQ; Hwu P; Radvanyi LG
Cancer J; 2012; 18(2):160-75. PubMed ID: 22453018
[TBL] [Abstract][Full Text] [Related]
40. Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma.
Falletta P; Sanchez-Del-Campo L; Chauhan J; Effern M; Kenyon A; Kershaw CJ; Siddaway R; Lisle R; Freter R; Daniels MJ; Lu X; Tüting T; Middleton M; Buffa FM; Willis AE; Pavitt G; Ronai ZA; Sauka-Spengler T; Hölzel M; Goding CR
Genes Dev; 2017 Jan; 31(1):18-33. PubMed ID: 28096186
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
